Who Owns Sunrise Medical? A Cost Controller’s Guide to Mammography vs. Point-of-Care Testing

I manage clinical equipment procurement for a ~300-person multispecialty center. Our capital budget is about $1.4 million a year, and I’ve spent the past seven years building spreadsheets that make finance squirm. When leadership asked whether we should invest in mammography or a point-of-care testing (POCT) program, I knew the answer couldn’t be “both are useful.” It had to be: which one creates more total value for the kind of patients we actually see?

Before the comparison, let’s settle a naming issue that trips up procurement teams. Who owns Sunrise Medical? If you’re searching for the mobility equipment company—the one behind wheelchairs and rehab products—public trade coverage indicates it was acquired by Cortec Group in 2019. The Sunrise Multispecialist Medical Center is not the same organization. Don’t send a purchase order for a power wheelchair to a clinic. I learned that one the hard way (embarrassing, but true). Pay attention to the legal entity, not the brand name.

The Cost Controller’s Comparison Framework

The real comparison wasn’t “which device should we buy?” It was “which diagnostic capability should we build?” That changes the question from a sticker price to a total-cost-of-ownership (TCO) question.

Mammography is low-dose X-ray imaging of breast tissue for screening and diagnosis. It has a high fixed cost, long lifecycle, and a distinct billing code.

Point-of-care testing means running lab tests at or near the patient—glucose, rapid strep, INR, urinalysis. It has a lower entry cost, but every test consumes a cartridge, strip, or kit.

Dimension 1: Upfront Cost vs. Total Cost of Ownership

Everyone asks about purchase price first. From our 2024 quotes, a new mammography system landed between $100,000 and $180,000 installed. A POC analyzer could be $5,000 to $25,000. On paper, that looks like a 10x difference.

Then I built the five-year TCO model. The gap closed fast. The mammography machine had fewer hidden consumables. Yes, it needed service contracts and quality audits, but those were predictable. The POC program had a firehose of ongoing costs: test strips, controls, calibration, temperature logs, training, and repeat tests.

Here’s the surprise: we estimated POC consumables at $18,000 per year. Actual spend in the first twelve months was almost $27,000. Staff re-ran tests when results looked unusual, and we paid for every cartridge. The “cheap” option had the higher hidden cost.

Conclusion: Mammography wins on forecastability. The sticker price is higher, but the next five years are easier to predict. POCT’s total cost curve is steeper than the vendor’s brochure suggests.

Dimension 2: Workflow and Labor

Mammography needs a trained technologist, a private room, and a radiologist read. POCT can be run by licensed clinical staff while the patient is still in the room. That sounds like POCT is faster. For a single test, it is.

But the labor math is not what I expected. We do about five mammograms per day and about 60 POCT tests per day. The mammography workflow is discrete: patient schedules, tech runs the exam, radiologist reads, report gets sent. POCT is embedded into a hundred patient visits. Every result still needs to be documented, entered, reviewed, and communicated. In our analysis, each POCT result saved lab turnaround time but added about four minutes of bedside documentation and follow-up. At 60 tests a day, that’s four extra hours of staff time. We didn’t budget for that.

Conclusion: POCT wins on convenience, but loses on hidden labor. At high volumes, the nurse becomes the bottleneck. At low volumes, the radiologist is the bottleneck. For us, POCT required more labor hours per diagnostic result than mammography.

Dimension 3: Compliance and Quality Risk

Mammography has heavier regulatory requirements. According to the FDA, facilities must be certified under the Mammography Quality Standards Act (MQSA). Room shielding, annual surveys, technologist certification, and equipment accreditation all add cost. But they’re obvious costs. You see them coming.

POCT compliance is less obvious. Many tests are CLIA-waived, but every operator still needs annual competency validation. That means tracking who is trained, who renewed their competency, and who used the wrong test strip. It’s HR-hours, not equipment dollars. It doesn’t show up on a capital request, so leadership ignores it.

Conclusion: Mammography’s compliance burden is capital-heavy but visible; POCT’s compliance burden is labor-heavy and invisible. In a multispecialty center, invisible labor is usually the more dangerous cost.

Dimension 4: Revenue and Reimbursement

Mammography creates a separate, billable service. It has its own CPT code, its own patient pathway, and its own revenue line. POCT is often bundled into the office visit. That means it can improve clinical outcomes and patient satisfaction without generating a separate reimbursement stream.

At our center, that changed the financial conversation. The mammography suite could be justified by direct revenue projections. The POC program had to be justified by efficiency and patient experience. Both are valid. But if the goal is to make the service line self-sustaining, mammography is easier to defend in a budget meeting.

Conclusion: Mammography wins on revenue clarity. POCT is operationally valuable, but don’t expect it to carry its own weight on a contribution margin report the same way.

Dimension 5: Brand and Patient Perception

Now we get to the part that doesn’t belong in a spreadsheet. After we launched the mammography suite, referrals from two obstetrics practices in our area went up about 14% in the first quarter. The POCT program never came up in patient feedback. A mammography suite signals that a center does serious women’s health. Point-of-care testing is invisible to the community.

I’m not saying POCT doesn’t matter. It matters clinically. But when you’re building a multispecialty brand, the expensive, visible diagnostic service creates trust in a way that a rapid strep test never will. Patients don’t know what CLIA-waived means. They know what a mammography suite means.

Conclusion: Mammography wins on brand perception. And in healthcare procurement, brand perception is not fluff—it’s patient volume.

Why Prosthetic Limb Services Need the Same TCO Question

The same thinking applies to a prosthetic limb program. Many centers look at prosthetics as a product line. But a prosthetic limb is not a catalog item. It’s a patient-specific project: custom socket, iterative fitting, insurance preauthorization, refits, gait training.

We evaluated a turnkey prosthetic program that looked affordable on paper. The hidden costs were in the fittings and denials. We ended up partnering with a regional certified prosthetist instead. Not because the partner was cheap, but because the per-patient cost was predictable and the outcome quality was easier to control. Same TCO lesson: don’t compare list prices; compare the full cost of producing a good health outcome.

So Which Do You Choose?

There’s no universal winner. But there are clear starting points:

• If you run an urgent care or primary care model, point-of-care testing is probably the better first investment.
• If you’re building an outpatient multispecialty center with women’s health, oncology, or breast surgery referrals, start with mammography.
• If you’re trying to do both, build the TCO model before you commit. You’ll probably be surprised by which one is actually ready for prime time. We were.

Prices are based on internal 2024 quotes and public pricing available at the time of writing. Verify current rates, ownership, and regulatory requirements before making your decision.